

GLAXOSMITHKLINE PLC  
Form 6-K  
March 25, 2019

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**of the Securities Exchange Act of 1934**

**March 25, 2019**

**GlaxoSmithKline plc**  
**(Name of registrant)**

**GlaxoSmithKline Capital plc**  
**(Name of registrant)**

**980 Great West Road, Brentford,**  
**Middlesex, TW8 9GS**  
**(Address of principal executive offices)**

**980 Great West Road, Brentford,**  
**Middlesex, TW8 9GS**  
**(Address of principal executive offices)**

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

THIS REPORT ON FORM 6-K SHALL BE DEEMED TO BE INCORPORATED BY REFERENCE IN THE PROSPECTUS INCLUDED IN THE REGISTRATION STATEMENT ON FORM F-3 (FILE NOS. 333-223982 AND 333-223982-02) OF GLAXOSMITHKLINE PLC AND GLAXOSMITHKLINE CAPITAL PLC AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS FURNISHED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED.

GlaxoSmithKline plc and GlaxoSmithKline Capital plc. hereby incorporate by reference the following exhibits to this report on Form 6-K into their Registration Statement on Form F-3 (File Nos. 333-223982, 333-223982-02).

| Exhibit<br>No. | Description of Document   |
|----------------|---|
| 5.1            | <u>Opinion of Cleary Gottlieb Steen &amp; Hamilton LLP, special U.S. counsel to GlaxoSmithKline plc and GlaxoSmithKline Capital plc.</u>    |
| 5.2            | <u>Opinion of Cleary Gottlieb Steen &amp; Hamilton LLP, special English counsel to GlaxoSmithKline plc and GlaxoSmithKline Capital plc.</u> |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc and**

**GlaxoSmithKline Capital plc**

(Registrants)

Date: March 25, 2019

By: /s/ Victoria Whyte  
Authorised Signatory for and on behalf of  
GlaxoSmithKline plc and  
GlaxoSmithKline Capital plc

*[Signature page to Form 6-K]*